



GOODWIN



Mayan Katz

Partner

Spoken Languages

English | Hebrew

New York

+1 212 459 7269

Mayan Katz is a partner in Goodwin's Life Sciences group. Mr. Katz represents private and public companies and investors in the pharmaceutical, medical device, biotechnology and digital health sectors throughout the corporate lifecycle.

Mr. Katz advises both buyers and sellers on a wide range of mergers and acquisitions, including structured transactions, divestitures, spin-outs, joint ventures, and strategic alliances. He also has extensive experience counseling on startup and formation matters, venture capital financings, general corporate matters, deSPAC transactions and other strategic and complex transactions. Mr. Katz is a leader in the firm's Israel practice and also maintains an active pro bono practice. He joined the firm in 2018.

REPRESENTATIVE MATTERS

Mergers and Acquisitions and Strategic Transactions

- Johnson & Johnson and its subsidiaries in connection with:
 - the sale of one of its drug product lines to Baxter International
 - the strategic alliance with Apple to deploy the Apple Watch to detect atrial fibrillation and the launch of the Heartline™ Study
 - the transfer of collaboration rights and assets to Pharma Mar
 - the \$155 million sale of injectable anesthesia and pain management products to Piramal Enterprises' critical care division*
 - the spin-out of Tusker Medical Inc. to Apple Tree Partners*
- EQRx in connection with:
 - its \$1.8 billion proposed business combination with CM Life Sciences III
- Clarus Therapeutics in connection with:
 - its business combination with Blue Water Acquisition Corp.
 - its senior debt financing of up \$75 million
 - its convertible note financings
- bluebird bio in its strategic alliance with National Resilience and the related acquisition by Resilience of

bluebird's manufacturing facility in North Carolina for \$110 million

- Centessa Pharmaceuticals in its \$250 million financing round in parallel with the simultaneous acquisition by Centessa of 10 private biotech companies across four jurisdictions
- Cadent Therapeutics in its acquisition by Novartis for up to \$770 million, including an upfront payment of \$210 million and up to \$560 million in milestone payments
- Cerevel Therapeutics in its business combination with ARYA Sciences Acquisition Corp. II
- AMAG Pharmaceuticals in connection with:
 - the divestment of its women's health assets
 - the sale of its rights to Intrarosa® to Millicent Pharma for up to \$125 million
- Ikena Oncology in its acquisition of Amplify Medicines
- Shields Health Solutions in its equity investments from Welsh, Carson, Anderson & Stowe and Walgreen Co.
- Zealand Pharma in its \$205 million royalty and milestone monetization from Royalty Pharma
- Enterome in its global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical
- E-commerce company Lazada Group on the \$1 billion sale of a controlling stake in the company to Alibaba, which was named "M&A Deal of the Year: Southeast Asia" at The Asian Lawyer's 2017 Asia Legal Awards.*
- A private equity firm in its investment in a leading Mid-Atlantic eye care platform.*
- A wholly-owned subsidiary of an S&P 500 pharmaceutical company in its equity and debt financing of a private life sciences company*
- An affiliate of a leading biopharmaceutical company in an asset spin off and a collaboration and license agreement with a company co-founded by a US-based investment firm*
- A multinational medical device company in its \$51 million acquisition of assets and a subsequent joint venture*
- A leading 3D printing company on a series of substantial acquisitions for \$695 million*
- A multinational technology corporation on a series of cross-border acquisitions*

* Denotes experience prior to joining Goodwin.

Venture Capital Financings

- Nested Therapeutics launch and its \$125 million in financing, including its initial financing by Versant Ventures and its \$90 million Series A financing
- Cathay Health, Polaris Partners, and Newpath Partner in their investments as lead investors in the \$60 million Series A financing of Kojin Therapeutics
- Johnson & Johnson and its subsidiaries in connection with the investment as lead investor of the \$1.3 billion Series B financing of Grail, Inc., which was named LMG Life Sciences 2017 "Impact Deal of the Year"*
- EQRx in connection with:
 - its \$500 million Series B financing
 - its \$200 million Series A financing
- Stablix Therapeutics in its \$63 million Series A financing
- Orbia Ventures in connection with:
 - its investment as lead investor in the \$21 million Series B financing of Battery Resources

- its investment in Silvec Biologics
- its \$3 investment in SeeTree

- Augmedics in its \$36 million Series C financing
- 5AM Ventures in its investment as lead investor in the \$78 million Series A financing and \$120 million Series B financing of Artiva Biotherapeutics
- Perceptive Advisors in its investment as lead investor in the \$85 million Series B financing of Athira Pharma
- A healthcare company in its reorganization and series seed financing*
- A private Israeli company in its \$15.5 million Series B financing from several venture capital funds*
- Mr. Katz also represents leading life sciences venture capital and investment firms in connection with their portfolio investments and related matters.

** Denotes experience prior to joining Goodwin.*

Capital Markets Transactions

- Vascular Biogenics in its \$28.3 million public follow-on offering on The Nasdaq Global Market
- The underwriters in Itamar Medical's \$40 million public offering on The Nasdaq Capital Market
- The underwriters in BioLineRx's \$15 million follow-on offering on The Nasdaq Capital Market
- Advaxis in its \$20 million public follow-on offering on The Nasdaq Capital Market
- Zealand Pharma in its upsized \$90 million IPO on The Nasdaq Global Select Market*
- A leading 3D printing company in its \$481 million follow-on public offering on The Nasdaq Global Select Market*
- A leading 3D printing company in its merger and subsequent registration statement on The Nasdaq Global Select Market*

** Denotes experience prior to joining Goodwin.*

Pro Bono

Mr. Katz is an active participant in Goodwin's Neighborhood Business Initiative and a member of its Steering Committee in the New York Office. He has participated and counseled on multiple pro bono legal clinics, and regularly advises non-profit organizations in connection with corporate governance and transactional matters, including on mergers of Connecticut-based organizations.

AREAS OF PRACTICE

Mergers & Acquisitions

- Venture Capital

Life Sciences

- Cannabis

Technology

- Medtech

PROFESSIONAL EXPERIENCE

Prior to joining Goodwin in 2018, Mr. Katz was an associate at an international law firm in New York and at Meitar Law Offices in Tel Aviv.

Prior to his studies at Tel Aviv University, Mr. Katz served as an officer in the Israel Defense Forces.

CREDENTIALS

Education

Master of Laws, 2015

University of Pennsylvania Law School
(with distinction)

Bachelor of Laws, 2011

Tel Aviv University
(Dean's Honor List for 2009)

BA, Economics, 2011

Tel Aviv University

Admissions

Bars

- Israel
- New York

PUBLICATIONS

- Speaker, "Playing on a Global Stage: Understanding Cyber Trends and Making the Big Deals," Cyber Week Tel Aviv, June 29, 2022
- Author, "Hedging COVID-19 Pandemic Risks in Early-Stage Financings," Life Sciences Perspectives Blog (2021)
- Author, Down Rounds 101, Life Sciences Perspectives Blog (2020)
- Moderator, "Digital Health Privacy: A Panel Discussion", UJA Federation New York (2020)
- Moderator, "The Regulation of Digital Health and Health IT", New York Healthcare + Biotech CLE Day (2019)
- Co-Author, Foreword: Empirical Legal Studies, 34 Tel Aviv University Law Review 293 (2011)
- While attending law school, Mr. Katz was the Editor-in-Chief (Vol. 34) and an Editorial Board Member (Vol. 33) of Tel Aviv University Law Review (Iyunei Misphat).